Drug Repurposing: A Promising Approach for Patients With Angina and Non-Obstructive Coronary Artery Disease (ANOCA)
June 2023
in “
Frontiers in Cardiovascular Medicine
”
TLDR Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
The document discusses the potential of drug repurposing, particularly for treating angina and non-obstructive coronary artery disease (ANOCA), a condition affecting about 40% of patients undergoing diagnostic coronary angiography. Drug repurposing is cost-effective and time-saving as these drugs have already undergone development. The paper identifies Soluble Guanylate Cyclase (sGC) Stimulators and Endothelin-1-receptor (ET-1) blockers, both originally approved for pulmonary hypertension, as promising candidates for ANOCA treatment. However, clinical trials are needed to confirm their safety and efficacy. The document also discusses innovative methods for drug repurposing, including the use of immortalized human cancer cell lines and HER-linked DNA Databases to pair genomic and pharmacological data.
